-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The fourth batch of centralized drug procurement has already reached the fourth batch of drugs.
While bringing the benefits of price cuts to patients, it has profoundly affected the performance of listed pharmaceutical companies and the capital market, and has also changed the past trend of high sales expenses for pharmaceutical companies.
At the same time, centralized procurement is also forcing local pharmaceutical companies to innovate their R&D models.
On the one hand, centralized procurement is forcing pharmaceutical companies to increase R&D investment.
Among them, from the perspective of the amount of R&D support, in 2020, a total of 142 companies will increase their R&D investment in 2020 compared with the previous year.
In addition, the R&D expenses of many pharmaceutical companies in subdivisions have also risen to varying degrees.
It can be seen that Chinese pharmaceutical companies are gradually transforming from generic drugs with low technical gold content to high-end generic drugs and innovative drugs.
On the other hand, due to the time-consuming, high cost, and high risk of new drug research and development, for companies with a relatively weak research and development foundation, choosing the License-in (authorized introduction) model is also a direction.
According to incomplete statistics, in the first quarter of 2021, as the market for innovative drug R&D and commercial cooperation continues to be hot, the number of domestic license-in projects in the first quarter has reached as high as 24, involving BeiGene, Zai Lab, and Fuhong Han Leading Biopharma/Biotech companies such as Lin Lin and Silidi Pharmaceuticals, as well as large local companies such as Hengrui Pharmaceuticals, Hausen Pharmaceuticals, Qilu Pharmaceuticals, Yangzijiang, Simcere Pharmaceuticals, Harbin Pharmaceutical Group, etc.
From the perspective of the industry, the introduction of overseas varieties has greatly improved the efficiency of new drug research and development, while rapidly enriching China's innovative drug pipeline and accelerating the progress of clinical projects.
